Correlation Between Viracta Therapeutics and Amylyx Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and Amylyx Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and Amylyx Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viracta Therapeutics and Amylyx Pharmaceuticals, you can compare the effects of market volatilities on Viracta Therapeutics and Amylyx Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of Amylyx Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and Amylyx Pharmaceuticals.

Diversification Opportunities for Viracta Therapeutics and Amylyx Pharmaceuticals

-0.65

Correlation Coefficient

Viracta Therapeutics  Amylyx Pharmaceuticals

Excellent diversification

The 3 months correlation between Viracta and Amylyx is -0.65. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and Amylyx Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Amylyx Pharmaceuticals and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with Amylyx Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Amylyx Pharmaceuticals has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and Amylyx Pharmaceuticals go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and Amylyx Pharmaceuticals

Given the investment horizon of 90 days Viracta Therapeutics is expected to under-perform the Amylyx Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Viracta Therapeutics is 1.35 times less risky than Amylyx Pharmaceuticals. The stock trades about -0.18 of its potential returns per unit of risk. The Amylyx Pharmaceuticals is currently generating about 0.29 of returns per unit of risk over similar time horizon. If you would invest  216.00  in Amylyx Pharmaceuticals on September 2, 2024 and sell it today you would earn a total of  338.00  from holding Amylyx Pharmaceuticals or generate 156.48% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Viracta Therapeutics  vs.  Amylyx Pharmaceuticals

Viracta Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Amylyx Pharmaceuticals

Risk-Adjusted Performance

22 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Amylyx Pharmaceuticals are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak essential indicators, Amylyx Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Viracta Therapeutics and Amylyx Pharmaceuticals

The main advantage of trading using opposite Viracta Therapeutics and Amylyx Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, Amylyx Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amylyx Pharmaceuticals will offset losses from the drop in Amylyx Pharmaceuticals' long position.

The idea behind Viracta Therapeutics and Amylyx Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.